Fungicide Resistance Status and Chemical Control Options for the Brassica Pathogen Pyrenopeziza Brassicae

Kevin M. King,Diana E. Bucur,Faye Ritchie,Nichola J. Hawkins,Agata M. Kaczmarek,Yabing Duan,Steven Kildea,Jonathan S. West,Bart A. Fraaije
DOI: https://doi.org/10.1111/ppa.13441
2021-01-01
Plant Pathology
Abstract:Pyrenopeziza brassicae causes leaf spot disease of Brassicaceae in Europe/Oceania (lineage 1) and North America (lineage 2). In Europe, fungicides currently used for disease management are sterol 14 alpha-demethylase (CYP51) inhibitors (azoles), quinone outside inhibitors (QoIs), and succinate dehydrogenase inhibitors (SDHIs); methyl benzimidazole carbamates (MBCs) are no longer applied. In this study, in vitro screening revealed European populations (collected 2018-2020) had shifted towards decreased azole sensitivity, but the North American population (2014-2016) was highly sensitive. Genotyping revealed CYP51 substitutions G460S or S508T were prevalent in European populations, often with a CYP51 promoter insert. Compared to wildtype CYP51 isolates, those with G460S plus an insert (44/46/151/210/302 bp) were c.25-32-fold and c.50-fold less sensitive to tebuconazole and prochloraz, respectively; those with S508T plus an insert (44/46/151/233 bp) were c.9-15-fold and c.25-40-fold less sensitive to tebuconazole and prochloraz, respectively. Selection for G460S (quantified via pyrosequencing) under different fungicide regimes was investigated in UK field trials, but G460S levels were high (c.76%) before treatment, so further selection during the trials was unclear. Despite the high G460S frequency and low disease pressure, yield data indicated measurable benefit for both azole- and non-azole-based programmes. In vitro screening against the MBC carbendazim showed European populations were predominantly moderately resistant/resistant; the North American population was sensitive. European and North American populations were sensitive to QoI (pyraclostrobin) and SDHI (penthiopyrad) fungicides. Results support an azole plus QoI/SDHI mixing partner for robust disease control and decreased risk of resistance, with continued sensitivity monitoring to ensure optimal strategies are deployed.
What problem does this paper attempt to address?